Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Oct 30, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell

This study evaluated the effectiveness of maintenance therapy with rituximab (Rituxan) in elderly patients with newly diagnosed follicular lymphoma (FL). This study concluded that maintenance rituximab treatment improved survival outcomes in these patients in a real-world setting.

Some background

Chemoimmunotherapy containing rituximab remains the standard first-line (primary) treatment for patients with FL. Maintenance therapy with rituximab is often given to patients who achieve at least a partial response (tumor shrinkage) after initial treatment. Maintenance therapy is low-intensity therapy that is given over an extended period of time. The goal of this therapy is to delay relapse rather than cure the disease. The effectiveness of rituximab maintenance (RM) in elderly patients with FL remains under investigation.

Methods & findings

This study involved the medical records of 232 patients 65 or older with newly diagnosed FL. Patients received first-line chemoimmunotherapy followed by RM (68.1%) or no maintenance therapy (31.9%; control group). Patients were followed-up for an average of 5.38 to 8.12 years.

The average overall survival (time from treatment patients are alive; OS) was 8.12 years in the no maintenance therapy group. The average OS was not reached (was longer than the follow-up period) in the RM group. Five-year OS rate was significantly higher in the RM group (83.7%) compared to the control group (64.3%).

The average progression-free survival (the time patients are alive without tumor growth or spread; PFS) was significantly higher in the RM group (10.88 years) compared to the control group (3.58 years). Five-year PFS rate was significantly higher in the RM (71.1%) group compared to the no maintenance therapy group (40.2%).

Maintenance therapy with rituximab was significantly associated with a 61.9% lower risk of disease progression and a 53.3% lower risk of mortality.

The bottom line

This study concluded that maintenance rituximab treatment improved survival outcomes in elderly patients with FL in a real-world setting.

The fine print

This study was retrospective, meaning it looked back in time to analyze data.

Published By :

Leukemia Research

Date :

Aug 31, 2018

Original Title :

The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group.

click here to get personalized updates